• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • China’s vaccine regulator achieves Maturity Level 3 from World Health Organization

China’s vaccine regulator achieves Maturity Level 3 from World Health Organization

China's vaccine regulator
Friday, 14 October 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China’s vaccine regulator achieves Maturity Level 3 from World Health Organization

China’s vaccine regulator is being ranked at Maturity Level 3 by the World Health Organization (WHO).

The Chinese National Regulatory Authority (NRA) is now classed as being at a functional level of maturity according to the WHO’s global classification system for national regulatory authorities for medical products. This means that China has a stable, well-functioning and integrated regulatory system to ensure the quality, safety, and effectiveness of vaccines that are manufactured, imported or distributed in the country.

Highlights

  • The World Health Organization undertook a review of the Chinese NRA back in April 2014 based on the WHO vaccines assessment tool indicators at that time. The WHO undertook subsequent benchmarking activities in 2019 and 2021 indicating recommendations for actions.
  • Further to those assessments, a WHO expert team conducted a formal benchmarking of the NRA (represented by the National Medical Products Administration) in July 2022 using the most recent and more comprehensive assessment tool: the WHO Global Benchmarking Tool.
  • As the National Medical Products Administration (NMPA) had taken into consideration and addressed the recommendations made by the WHO as result of the assessments already undertaken in 2014, 2019 and 2021, the WHO was able to confirm China’s Maturity Level 3 (ML3) achievement for the regulation of vaccines in China.
  • During the benchmarking, WHO noted that the NMPA had considered and addressed recommendations made following the activities in 2014, 2019 and 2021, confirming the country’s ML3 achievement for the regulation of vaccines in China.
  • WHO Regional Director for the Western Pacific, Dr Takeshi Kasai, congratulated the People’s Republic of China for achieving ML3 for their vaccine regulation system. It is recognized as a significant step for the global supply of vaccines because of China’s role as a manufacturer, as well as being an important step for public health in China. Dr Takeshi further recommended the NMPA and respective institutions to scale up their effort towards regulating medicines and other medical products to achieve the highest level of maturity which is level 4.

Further information

If you would like to learn more about vaccine manufacture and registration in China or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods please contact us.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

NMPA 2020 Annual Report of Medical Device & IVD Registrations in China
Positive development for remote inspections to obtain SELO China manufacturer license
NMPA Publishes 6 Regulatory Drafts Concerning Clinical Trials for Medical Devices and IVDs

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Cisema announces Hamish King as new CEO

    Cisema announces Hamish King as new CEO

    Cisema, the regulatory affairs consultancy and ...
  • China medical device standards management 2022

    China medical device standards management 2022 annual report issued

    China medical device standards management 2022 ...
  • Medical device registrations China 2022

    Medical device registrations China 2022 annual report issued

    Medical device registrations China 2022 Annual ...
  • China UDI medical device third batch

    China UDI medical device third batch – implementation date released

    China UDI medical device third batch implementa...
  • CCC electronics self-inspection pilot work

    CCC electronics self-inspection pilot work launched by the CNCA

    CCC electronics self-inspection pilot work was ...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP